JW (Cayman) Therapeutics Future Growth
Future criteria checks 2/6
JW (Cayman) Therapeutics is forecast to grow earnings and revenue by 27.7% and 49.9% per annum respectively. EPS is expected to grow by 29.7% per annum. Return on equity is forecast to be -25.6% in 3 years.
Key information
27.7%
Earnings growth rate
29.7%
EPS growth rate
Biotechs earnings growth | 30.1% |
Revenue growth rate | 49.9% |
Future return on equity | -25.6% |
Analyst coverage | Low |
Last updated | 01 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,202 | -193 | -184 | N/A | 1 |
12/31/2025 | 575 | -470 | -450 | N/A | 2 |
12/31/2024 | 342 | -550 | -692 | N/A | 2 |
12/31/2023 | 196 | -681 | -621 | N/A | 2 |
6/30/2023 | 167 | -797 | -483 | -404 | N/A |
3/31/2023 | 157 | -822 | -560 | -470 | N/A |
12/31/2022 | 146 | -846 | -637 | -537 | N/A |
9/30/2022 | 121 | -849 | -681 | -594 | N/A |
6/30/2022 | 97 | -851 | -724 | -651 | N/A |
3/31/2022 | 64 | -777 | -711 | -606 | N/A |
12/31/2021 | 31 | -702 | -698 | -561 | N/A |
9/30/2021 | 15 | -998 | -638 | -498 | N/A |
6/30/2021 | -1 | -1,294 | -577 | -435 | N/A |
3/31/2021 | 0 | -1,479 | -488 | -348 | N/A |
12/31/2020 | N/A | -1,664 | -398 | -261 | N/A |
9/30/2020 | 3 | -1,295 | -386 | -227 | N/A |
6/30/2020 | 6 | -925 | -374 | -192 | N/A |
3/31/2020 | 6 | -779 | -338 | -190 | N/A |
12/31/2019 | 5 | -633 | -303 | -189 | N/A |
12/31/2018 | 0 | -273 | -150 | -106 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2126 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2126 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2126 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2126's revenue (49.9% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 2126's revenue (49.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2126 is forecast to be unprofitable in 3 years.